Success Metrics

Clinical Success Rate
100.0%

Based on 13 completed trials

Completion Rate
100%(13/13)
Active Trials
0(0%)
Results Posted
69%(9 trials)

Phase Distribution

Ph phase_1
8
62%
Ph phase_2
5
38%

Phase Distribution

8

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
8(61.5%)
Phase 2Efficacy & side effects
5(38.5%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

13 of 13 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

13

all time

Status Distribution
Completed(13)

Detailed Status

Completed13

Development Timeline

Analytics

Development Status

Total Trials
13
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 18 (61.5%)
Phase 25 (38.5%)

Trials by Status

completed13100%

Recent Activity

0 active trials
Showing 5 of 13
completedphase_2

Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia

NCT01109069
completedphase_2

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma

NCT01478581
completedphase_1

Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL

NCT01752426
completedphase_2

Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia

NCT01614821
completedphase_2

Phase 2 Study of the Combination of Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients

NCT01520519
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT01109069Phase 2

Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia

Completed
NCT01478581Phase 2

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma

Completed
NCT01752426Phase 1

Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL

Completed
NCT01614821Phase 2

Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia

Completed
NCT01520519Phase 2

Phase 2 Study of the Combination of Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients

Completed
NCT01704963Phase 1

A Study to Evaluate the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Patients With Recurrent Mature B-Cell Neoplasms

Completed
NCT01236391Phase 2

Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)

Completed
NCT01217749Phase 1

Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL

Completed
NCT01767948Phase 1

A Study to Evaluate the Pharmacokinetics of PCI-32765 in Participants With Varying Degrees of Hepatic Impairment

Completed
NCT01292135Phase 1

Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)

Completed
NCT01105247Phase 1

Safety of PCI-32765 in Chronic Lymphocytic Leukemia

Completed
NCT00849654Phase 1

Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma

Completed
NCT01763021Phase 1

A Study to Assess the Effect of Rifampin on the Pharmacokinetics of PCI-32765 in Healthy Participants

Completed

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13